Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity Ackerman SE, et al., Nature Cancer (2020)
About Andrea Tu
This author has yet to write their bio.
Meanwhile lets just say that we are proud Andrea Tu contributed a whooping 52 entries.
Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement ADC Review
U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in the Development of BDC-1001 ADC Review
Randall Schatzman, Ph.D. to Lead Growth of Immune- Stimulating Antibody Conjugates at Bolt Biotherapeutics ADC Review
How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy ADC Review
Bolt Biotherapeutics Nabs $93.5M to Push Provenge Inventor’s New Idea Deeper in the Clinic Endpoints News
Bolt’s Myeloid Twist on ADCs Charged up with $93.5M series C BioCentury
Pfizer-Backed Bolt Therapeutics Strikes $93.5M Funding Round As Lead Med Hits the Clinic Fierce Biotech
Agonist ecstasy? HER2 (and more) ‘Bolt’-on strategy draws $93.5M series C BioWorld
You acknowledge that the personal information you provide to Bolt Biotherapeutics will be processed to respond to your request or inquiry. For more information, please review our Privacy Notice .